Decreasing tumor size of thyroid cancer in Germany: Institutional experience 1995-2009

European Journal of Endocrinology

Volumn 163, Issue 1, 2010, Pages 111-119

  Machens, Andreas ^a   Dralle, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREND STUDY; TUMOR VOLUME;

ADULT; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 77954114756     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0203     Document Type: Article

References (35)

1. Hall SF, Walker H, Siemens R & Schneeberg A. Increasing detection and increasing incidence in thyroid cancer. World Journal of Surgery 2009 33 2567-2571.
2. Davies L &Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 2006 295 2164-2167.
3. Colonna M, Guizard AV, Schvartz C, Velten M, Raverdy N, Molinie F, Delafosse P, Franc B & Grosclaude P. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983-2000). European Journal of Cancer 2007 43 891-900.
4. Netea-Maier RT, Aben KKH, Casparie MK, den Heijer M, Grefte JMM, Slootweg P & Hermus A. Trends in incidence and mortality of thyroid carcinoma in the Netherlands between 1989 and 2003: correlation with thyroid fine-needle aspiration cytology and thyroid surgery. International Journal of Cancer 2008 123 1681-1684.
5. Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR & Anderson WF. Gender is an age-specific effect modifier for papillary cancer of the thyroid gland. Cancer Epidemiology, Biomarkers and Prevention 2009 18 1092-1100.
6. Sassolas G, Hafdi-Nejjari Z, Remontet L, Bossard N, Belot A, Berger-Dutrieux N, Decaussin-Petrucci M, Bournaud C, Peix JL, Orgiazzi J, Borson-Chazot F & Group of Pathologists of the Rhône Alpes Region. Thyroid cancer: is the incidence rise abating. European Journal of Endocrinology 2009 160 71-79.
7. Machens A, Holzhausen HJ, Lautenschladie;ger C, Nguyen Thanh P & Dralle H. Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma. A multivariate analysis of clinical risk factors. Cancer 2003 98 712-719.
8. Machens A, Hauptmann S & Dralle H. Referral bias in thyroid cancer surgery: direction and magnitude. European Journal of Surgical Oncology 2008 34 556-562. (Pubitemid 351514888)
9. Machens A & Dralle H. Age disparities in referrals to specialist care for papillary thyroid cancer. European Journal of Surgical Oncology 2009 35 1312-1317.
10. World Health Organisation. International Histological Classification of Tumours, edn 2, pp 7-12. Berlin, Germany: Springer, 1988.
11. DeLellis RA, Lloyd RV, Heitz PU & Eng C, Eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs, 57-91. Lyon, France: IARC Press, 2004.
12. Machens A, Lorenz K & Dralle H. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Annals of Surgery 2009 250 305-310.
13. Zhu C, Zheng T, Kilfoy BA, Han X, Ma S, Ba Y, Bai Y, Wang R, Zhu Y & Zhang Y. A birth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973-2004. Thyroid 2009 19 1061-1066.
14. Machens A, Schneyer U, Holzhausen HJ & Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. Journal of Clinical Endocrinology and Metabolism 2005 90 2029-2034. (Pubitemid 40586235)
15. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE & Devesa SS. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiology, Biomarkers and Prevention 2009 18 784-791.
16. Thamm M, Ellert U, Thierfelder W, Liesenkodie;tter KP & Vodie;lzke H. Iodine intake in Germany. Results of iodine monitoring in the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2007 50 744-749 (German).
17. Vodie;lzke H, Ludie;demann J, Robinson DM, Spieker KW, Schwahn C, Kramer A, John U & Meng W. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003 13 803-810. (Pubitemid 37070159)
18. Rego-Iraeta A, Pérez-Méndez LF, Mantinan B & Garcia-Mayor RV. Time trends for thyroid cancer in Northwestern Spain: true rise in the incidence of micro and lager forms of papillary thyroid carcinoma. Thyroid 2009 19 333-340.
19. Chen AY, Jemal A & Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009 115 3801-3807.
20. Trimboli P, Ulisse S, Graziano FM, Marzullo A, Ruggieri M, Calvanese A, Piccirilli F, Cavaliere R, Fumarola A & D'Armiento M. Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid 2006 16 1151-1155.
21. Hazard JB, Hawk WA & Crile G Jr. Medullary (solid) carcinoma of the thyroid - a clinicopathologic entity. Journal of Clinical Endocrinology and Metabolism 1959 19 152-161.
22. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A & Pacini F. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders. Journal of Clinical Endocrinology and Metabolism 2004 89 163-168. (Pubitemid 38183876)
23. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M & Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. Journal of Clinical Endocrinology and Metabolism 2007 92 450-455. (Pubitemid 46255279)
24. Machens A, Hoffmann F, Sekulla C & Dralle H. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocrine-Related Cancer 2009 16 1291-1298.
25. Rink T, Truong PN, Schroth HJ, Diener J, Zimny M & Grünwald F. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid 2009 19 327-332.
26. Scheuba C, Kaserer K, Moritz A, Drosten R, Vierhapper H, Bieglmayer C, Haas OA & Niederle B. Sporadic hypercalcitoninemia. Clinical and therapeutic consequences. Endocrine-Related Cancer 2009 16 243-253.
27. Lips CJM, Landsvater RM, Höppener JWM, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends M, Beemer FA, Brouwers-Smalbraak J, Jansen R, Ploos van Amstel HK, van Vroonhoven T & Vroom TM. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. New England Journal of Medicine 1994 331 828-835. (Pubitemid 24289709)
28. Wells SA, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, Norton JA & Donis-Keller H. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Annals of Surgery 1994 220 237-250. (Pubitemid 24313219)
29. Machens A, Niccoli-Sire P, Högel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H & European Multiple Endocrine Neoplasia (EUROMEN) Study Group . Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine 2003 349 1517-1725. (Pubitemid 37255037)
30. Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hüfner M, Niederle B, Brabant G & German Society for Endocrinology (DGE) - Thyroid Section. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendations. Experimental and Clinical Endocrinology and Diabetes 2004 112 52-58.
31. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W & and the European Thyroid Cancer Taskforce . European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787-803.
32. Kebebew E, Greenspan FS, Clark OH, Woeber KA & Grunwell J. Extent of disease and practice patterns for medullary thyroid cancer. Journal of the American College of Surgeons 2005 200 890-896. (Pubitemid 40744797)
33. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM & American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 16 1-33.
34. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM & American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167-1214.
35. Roman S, Lin R & Sosa JA. Prognosis of medullary thyroid carcinoma. Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006 107 2134-2142.